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Abstract
Introduction Human urine is a complex matrix of proteins,
endogenous peptides, lipids, and metabolites. The level of
any or all of these components can reflect the pathophys-
iological status of an individual especially of the kidney at
the time of urine collection. The naturally occurring
endogenous urinary peptides which are thought to be the
product of several proteolytic and degradation processes
may provide clinically useful biomarkers for different renal
and systemic diseases.
Materials and Methods To examine if specific differences
in the urinary peptidome (<10 kDa) occur at the time of
acute renal transplant rejection (AR), we undertook a study
of urine samples collected from biopsy-proven AR (n=10),
stable graft function (n=10), and healthy normal control
(n=10). The peptides (<10 kDa) were extracted and
fractionated with high-performance liquid chromatography
followed by matrix-assisted laser desorption/ionization
(MALDI) time-of-flight mass spectrometric (MS) analysis.
Results We identified 54 endogenous peptides, including
multiple peptides for Tamm–Horsfall protein (UMOD). A
panel of peptides are identified which discriminate renal
transplant patients with AR from stable graft. We have
shown that liquid chromatography followed by MALDI is a
useful tool to identify potential biomarkers, which after
verification with larger patient cohort can be used as a non-
invasive monitoring tool for renal transplant rejection.
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Renal transplantation . Proteomics . LCMALDI .
Urinary Peptidomics . Acute rejection .
Non-invasive biomarkers . Biomarker discovery
Abbreviations
AR Acute rejection
STA Stable graft function
HC Healthy normal control
THP Tamm–Horsfall protein




Urine is rich in proteins and peptides that could sample
both renal as well as systemic events [1]. Proteins and
endogenous peptides resulting from processes that include
glomerular filtration, apoptosis, and proteolytic degrada-
tions in urine may carry useful biomarkers for diseases
including acute allograft rejection (AR) of renal transplant
[2]. AR is a primary risk factor for graft functional decline,
chronic rejection, and accelerated graft loss [3, 4]. Eleva-
tions in the serum creatinine are nonspecific and may result
from many causes of graft dysfunction (e.g., acute tubular
necrosis, infection, drug toxicity), and AR can occur
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without an associated rise in the serum creatinine. The
invasive biopsy, the current gold standard, correlates poorly
with treatment response and prognosis and has associated
complications of pain, sedation, hematuria, arteriovenous
fistulae, graft thrombosis, and transfusion risk [5]. Therefore,
identification and validation of informative biomarkers for
non-invasive monitoring for acute rejection is a critical
unmet need in organ transplantation.
Urine has been analyzed to identify disease biomarkers
for diseases including coronary artery disease [6], renal cell
carcinoma [7], prostate cancer [8, 9], diabetes [10], and
renal diseases [11–16]. The analysis of naturally occurring
small molecular weight (MW) endogenous peptide analysis
is termed as “peptidomics.” Techniques such as capillary-
electrophoresis-coupled mass spectrometric analysis (CE
MS) [17, 18], liquid chromatography (LC) MS with off-line
coupled combination of reversed-phase high-performance
liquid chromatography (HPLC) and matrix-assisted laser
desorption/ionization time of flight mass spectrometry
(MALDI-TOF) [19], and magnetic bead separation fol-
lowed by MALDI-TOF [20] have been used to study the
urine peptidome. In this report, we develop and optimize a
method to analyze endogenous urinary peptides ranging
from 900 to 4,000 Da by label-free high-performance liquid
chromatography coupled with MALDI-TOF analysis and
identified potential biomarker peptides for acute rejection.
Materials and Methods
Samples
Thirty clinically annotated urine samples, collected as
early-morning midstream voids (with urine protein dip-
sticks ≤1+), were included in the study from three different
clinical phenotypes: renal transplant patients with biopsy-
proven acute rejection (AR; n=10), normal protocol
biopsies and stable graft function (STA; n=10), and age-
and gender-matched healthy normal controls (HC; n=10).
The transplant patients were matched for gender, race,
immunosuppression regimen, Donor type (living and
deceased), and time post-transplant (Table 1). As graft
function falls during an AR episode, as expected, the mean
graft function, based on calculated creatinine clearance in
milliliter per minute per 1.73 m2 [21], was lower for
patients with AR (85.1±46.7 for AR and 121±30.0 for
STA; P<0.01). Samples were collected between January
2005 and June 2007 as part of an ongoing Institutional
Review Board-approved study at Stanford University from
patients enrolled at Lucile Packard Children’s Hospital at
Stanford University.
Urine Collection, Initial Processing, and Storage
Fifty to 100 mL urine, collected in sterile containers, was
centrifuged at 2,000×g for 20 min at room temperature
within 1 h of collection. The supernatant was separated
from the pellet containing any particulate matter including
cells and cell debris. The pH of the supernatant was
adjusted to 7.0 and stored at −80°C until further analysis.
Recovery and Quantification of Urinary Protein
The urine processing method has been previously described in
detail by our group [22] and summarized in Fig. 1. Essentially,
urinary proteins were isolated by centrifugal filtration through
Amicon Ultra centrifugal filtration devices (10 kDa cutoff)
(Millipore, Bedford, MA, USA), at 3,000×g for 10 min at
10°C using swinging bucket rotors. After equilibration,
10 mL of urine supernatant was centrifuged for 20 min at
3,000×g at 10°C. The filtrate was recovered and saved for
peptidomic analysis. The retentate was washed twice with
10 mL 20 mM Tris–HCl (pH7.5). The final volume of the
retentate was saved for a separate study of urinary proteins.
Extraction of Low-MW Endogenous Peptides
The filtrates containing the low-MW urinary endogenous
peptides were extracted withWaters® Oasis® HLB Extraction
Cartridges (Waters Corporation, Milford, MA, USA). Briefly,











Mean age Mean GFR
(mL/min/1.73m2)
AR 10 5/5 5/5 5/5 12±5 83.3±52.2
STA 10 5/5 5/5 5/5 12±5 131.4±28.4
HC 10 n/a 5/5 n/a 8±4 n/a
Mean GFR by the Schwartz Formula [20], as expected, is significantly lower during the acute rejection episode when compared to patients
without rejection (p<0.01)
AR acute rejection, STA stable graft function, HC healthy normal control, SF steroid-free immunosuppression using tacrolimus and MMF
maintenance, SB steroid-based immunosuppression using steroids, tacrolimus, and MMF maintenance
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the cartridges were activated with 2 mL 100% acetonitrile
followed by equilibration with 5 mL 0.1% trifluoroacetic acid in
water. The pH of the sample was adjusted to pH3.0 by addition
of 50% trifluoroacetic acid (TFA) and passed through the
cartridge with 10 mL/min flow rate. The cartridge was washed
with 5 mL 0.1% TFA in water and eluted with 3 mL 70%
acetonitrile/0.1%TFA (flow rate no faster than 10 mL/min). The
volume of the eluted peptides was brought to 0.5 mL by the use
of SpeedVac. The peptides were extracted with 1 mL ethyl
acetate by vortexing for 1min. The aqueous layer was recovered
by discarding the upper organic layer, and the volume of the
extract was brought to 500μL by SpeedVac centrifugation.
Quantification of Endogenous Peptides and Proteins
2,4,6-Trinitrobenzenesulfonic Acid Assay The small-MW
peptides were quantified using a method published else-
where [23]. Briefly, a standard curve was generated with
glycine solution (10, 20, 30, 40, 50, 60, 70, 80μM).
Absorbance at 420 nm by 2,4,6-trinitrobenzenesulfonic acid
(TNBS) was measured.
Creatinine Assay Urine creatinine was measured using
Quantichrom™ Creatinine Assay Kit (DICT-500) (BioAssay
Systems, Hayward, CA, USA). The manufacturer’s manual
was followed for the assay.
Protein assay and Normalization The large-MW protein
fraction was quantified by bicinchoninic acid protein assay
(Pierce, Rockford, IL, USA). We used 2,4,6-trinitrobenze-
nesulfonic acid assay to normalize the peptide load onto the
LC fractionation. Since the samples have varied peptide
concentration as measured by the TNBS assay, we created
pools of samples to normalize for equal peptide content
contribution from each individual sample. Aliquots con-
taining 10 nmol were added from each individual samples
in all the three phenotypes (AR, STA, and HC) to make a
pool of 100 nmol peptides for each phenotype.
Sample Fractionation
Three nanomoles peptides were injected on a 100μm×
15 cm C18 reverse-phase column (Michrom) and eluted
with a gradient of 5% to 55% acetonitrile over 50 min using
a Michrom MS4 HPLC. Twenty-second fractions were
collected onto MALDI targets with a Probot fraction
collector (LC Packings). A total of 100 fractions were
collected and analyzed on 4700 MALDI-TOF/TOF (Applied
Biosystems) in MS mode. One microliter of matrix solution
containing 4.8 mg/ml α-cyano-4-hydroxycinnamic acid
(Agilent Technologies, Palo Alto, CA, USA and 30 fmol/μl
glu-fibrinopeptide (Sigma-Aldrich, St. Louis, MO, USA) was
automatically deposited by the Probot on each spot.
MS Data Collection and Analysis
To ensure reproducibility and robustness of measured
signal, three MS scans of 2,000 laser shots per spot were
performed for each MALDI plate. Ionization of glu-
fibrinopeptide was used as an internal control peptide and
was used for normalization of signal across experiments.
The MS data were collected in terms of mass to charge (m/z)
ratio, signal intensity, and the retention time. A key step of
data processing, transforming the large volume of raw data
into a list of nonredundant cross-category m/z features, while
simultaneously tracking associated sample source, retention
time, and intensity, was performed with the help of an in-
house informatics platform, “MASS-Conductor” (Ling,
unpublished). MASS-Conductor is an integrated suite of
algorithms, statistical methods, and computer applications
that interfaces with ABI, Thermo, and Agilent instrument
databases and discovers discrimative peptide features and
performs sample classification from protein mass spectrometry
data. MASS-Conductor implementation does two dimensional
clustering and tracks both m/z and HPLC retention time to
define mono-isotopic peak features. The peak-finding and
subsequent peak/retention time clustering procedure were
Fig. 1 A flowchart for peptidomic analysis of endogenous urinary
peptides. The schematic for urinary peptide extraction and processing
by LC MALDI method is shown. The detail of the method is
presented in “Materials and Methods” section
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developed and improved from previous descriptions [24, 25].
Figure 2 illustrates the biomarker discovery flow chart using
MASS-Conductor data mining tools to process HPLC data
sets.
Peptide Identification
Selected candidate biomarker peptides were analyzed by
tandem mass spectrometry (MS/MS) using a 4700 MALDI-
TOF/TOF (Applied Biosystems) inMS/MSmode. AllMS/MS
data were submitted for MASCOT database search for
identification purpose. All positive peptides identified were
manually reviewed.
Statistical Analysis
After retrieving the signal intensities for the endogenous
peptides from AR, STA, and HC, the relative ratio values
normalized against healthy control for AR/STA vs. HC
were calculated by the signal of AR/STA divided by the
signal of HC. The fold changes (AR vs. HC or STA vs. HC)
were then calculated based on these relative ratios. To
determine the high (or low) expression abundance and up-
(or down-) regulation in AR phenotype, two criteria were
used: (a) Fold change of AR vs. HC was larger (or less)
than 0 and (b) Fold change of AR vs. HC was larger (or
less) than the fold change of STA vs. HC. Therefore, four
groups of peptide signal intensity were categorized as (1)
high abundance and up-regulation in AR, (2) low abun-
dance and up-regulation in AR, (3) high abundance and
down-regulation in AR, and (4) low abundance and down-
regulation in AR. The box plots were drawn based on the
fold changes in each group; in addition, the line graphs
show that the signal intensity for each individual peptide
either increased or decreased in AR vs. STA.
LC MALDI on Individual Samples to Verify
Most Significant Peptide Biomarkers
We analyzed the 30 individual urine samples included in
the first discovery phase along with ten individual urine
samples from nonspecific proteinuric patients. The peptide
samples for analysis were prepared and processed by the
method, schematic of which is presented in Fig. 1.
Results
Protein and Peptide Recovery
We previously established a standard protocol for urine
collection and processing for urinary proteomics analysis
[22]. We followed the protocol to collect two separate
fractions of small-MW endogenous peptides and large-MW
proteins. Since our aim was to identify AR-specific
endogenous peptides, the filtration method using a mem-
brane with 10 kDa cutoff size served ideally.
When assayed by sodium dodecyl sulfate polyacrylamide
gel electrophoresis and linear mode MALDI-TOF, the
filtrates were found to be smaller than 6 kDa molecular size
(data not shown). The small-MW peptide fraction present in
the filtrate was quantified by 2,4,6-trinitrobenzenesulfonic
Fig. 2 Data processing pipeline
for peptidomic analysis using
LC MALDI. Data processing
involved transformation of large
volume of raw into a list of
nonredundant cross-category
m/z features keeping track of
sample source, retention time,
and intensity. MASS-Conductor
is an integrated suite of algo-
rithms, statistical methods, and
computer applications that
interface with Applied
Biosystems (Foster City, CA,
USA), ThermoElectron
(Waltham, MA, USA), and
Agillent Biotechnologies (Palo
Alto, CA, USA) instrument
databases and discover discri-
mative peptide features and
perform sample classification
from protein mass spectrometry
data
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acid assay which is based on the measurement of primary
amines and measuring the TNBS–primary amine conjugate
[26]. The mean peptide concentration in AR, STA, and HC
categories was 156.5±108.8, 344.6±121.5, and 378.4±
130.1μmol/dL, respectively. The mean protein concentration
was 6.8±3.8, 7.82±2.2, and 5.5±1.7 mg/dL in samples from
AR, STA, and HC, respectively. The mean urine creatinine
concentration was 59.1±49.3, 104.4±41.7, and 102.9±
38.2 mg/dL for AR, STA, and HC, respectively. Since
proteinuric urine samples were not included in the study,
there was no statistically significant difference in urine
protein concentration among the three categories of samples.
LC MALDI Analysis of Small-MW Endogenous Peptides
We tested for the optimal amount of endogenous peptides to
be fractionated for LC MALDI analysis. Results based on
the mass spectrometric data suggested 3 nmol equivalents as
the optimum amount (data not presented). Comparison of
analysis by spotting direct to plate vs. LC MALDI showed
large increase in number of features with the HPLC
fractionation followed by MALDI MS analysis. The MS
data consisted of a set of three sets of data points: the
retention time dimension, the m/z dimension, and the
intensity dimension. The “MASS-Conductor” software was
used to transform the large volume of raw data into a list of
nonredundant cross-category m/z features while simulta-
neously tracking associated sample source, retention time,
and intensity. Figure 2 illustrates the biomarker discovery
flow chart using Mass-Conductor data mining tools to
process LC MS data sets from pooled samples of respective
AR, STA, and HC categories. The analysis of ten repeated
LC MALDI scan of the three pooled samples of classes AR,
STA, and HC yielded 42.99 GB of raw data points
(354,561,673 rows of records), 2.99 GB peak data points
(6,295,689 rows of records), 528 MB monoisotopic feature
(ion containing only the most abundant isotopes) data points
(6,267,018 rows of records), and 10.52 MB unique mono-
isotopic feature data points across categories (106,760 rows
of records) equivalent to 26,690 peptides.
We analyzed MS data for AR-specific endogenous
peptides in terms of their relative abundance when
compared to their abundance in STA and HC. A set of 73
potential peptide biomarker candidates have been identified
whose level is 1.5-fold more or less in AR compared to
STA (Table 2). We calculated ratio of peptide signal
intensity and classified them as high abundance and low
abundance peptides by comparing their abundance with
their level in HC. We classified them into a total of four
groups. The first group comprised of (1) increased peptide
presence in AR and high abundance (n=6; Fig. 3D (II)), (2)
increased peptide presence in AR and low abundance (n=
31; Fig. 3B), (3) decreased peptide presence in AR and
high abundance, (n=5; Fig. 3A, and (4) decreased peptide
presence and low presence (n=31; Fig. 3C). The box plots
were drawn based on the fold changes in each group
(Fig. 3).
Identification of Potential Biomarker Endogenous Peptides
The 73 peptides listed in Table 2 were subjected to
identification by tandem mass spectrometry. To date, we have
identified 44 including several peptides originating from
proteins including collagen alpha-1(I) chain (COL1A1),
collagen alpha-3(V) chain (COL5A3), thyroid receptor-
interacting protein 6 (TRIP6), uromodulin (UMOD), albumin
D box-binding protein (DBP), B-2 microglobulin (B2M),
kininogen-1 (KNG1), protocadherin-1 (PCDH1), alpha-1-
microglobulin (AMBP), prostaglandin-H2 D-isomerase
(PTGDS), cartilage intermediate layer protein (CILP), Zn
finger protein 14 (ZNF14), vascular non-inflammatory
molecule 2 (VNN2), etc. These identifications include single
peptide per protein to multiple peptides per protein. A sample
MS/MS spectrum for a peptide from Tamm–Horsfall protein
(THP) is shown in Fig. 4 with corresponding MS in the inset.
There was no overwhelming presence of peptides from high-
abundance plasma proteins unlike in proteomics of intact
proteins using 2D DIGE in our studies using the urine of
renal transplant patients [22].
Verification of Most Significant Candidate Peptides by LC
MALDI on Individual Patients
We tested for the trueness of discovery of peptides with
MW of 1654.91, 1680.97, 1755.95, 1768.01, 1912.06, and
2040.16 Da on individual samples included in initial
discovery set (ten AR, ten STA, and ten HC, ten patients
with non-specific kidney injury (NS). Average normalized
signal intensities of the ten samples in each class have been
plotted with standard error of the mean (SEM; Fig. 5).
Student’s t test P values are calculated for each peptide
when the signal intensity was compared with other
phenotypes. All the peptides tested could be verified by
analyzing their presence in individuals in 40 individual
samples across the four phenotypes.
Discussion
Urinary peptides may provide much needed non-invasive
biomarkers for early diagnosis of acute rejection of renal
transplant. Unlike proteomics, where a smaller number
(hundreds), of larger-MW proteins are assessed, peptidomics
examines thousands of small-MW endogenous peptides in
[27]. Several top–down approaches have been used to
analyze naturally occurring endogenous peptides. Currently,
Clin Proteom (2009) 5:103–113 107












1,828.85 3.0 P12107 COL11A1 Collagen alpha-1
(XI-chain)
DGPPGPPGERGPQGPQGPV
2,176.00 1.8 P25940 COL5A3 Collagen alpha-3(V) chain QPGATGQPGPKGDVGQDGAPGIPG
968.58 1.7 P07911 UMOD Uromodulin SRVLNLGPI
1,468.81 1.5 P07911 UMOD Uromodulin VIDQSRVLNLGPIT
Decrease in AR
(n=5)
1,082.70 20.3 P61769 B2M B-2 microglobulin IQRTPKIQV
994.11 12.4
1,438.80 3.1
1,518.80 2.9 P61769 B2M B-2 microglobulin LSQPKIVKWDRDM







1,717.79 5.6 P17017 ZNF14 Zn Finger Protein YQEYEKQPCKCKAV
2,008.94 5.3 P25940 COL5A3 Collagen alpha-3(V) chain ERGPPGSRGERGQPGATGQP
2,206.00 5.0 P02452 COL1A1 Collagen Alpha-1(I) chain ADGQPGAKGEPGDAGAKGDAGPPGP
1,202.55 4.8 Q08174 PCDH1 Protocadherin-1 EEQPPNTLIGS
1,235.52 4.4 P25940 COL5A3 Collagen alpha-3(V) chain QGVVGPSGPPGPPG
1,060.58 4.2
1,322.61 3.6 P25940 COL5A3 Collagen alpha-3(V) chain GEPGPDGPPGRTGP
1,963.86 3.5 O95498 VNN2 Vascular non-inflammatory
molecule 2
PQVNWIPCQDPHRFGH
1,992.97 3.1 P25940 COL5A3 Collagen alpha-3(V) chain IGPPGEAGEKGDQGLPGVQGP
1,028.54 2.8 Q10586 DBP Albumin D box-binding
protein
PGGAPLPPPPP




1,076.56 2.3 O60909 B4GALT1 Beta-1,4-
galactosyltransferase 2
MSRLLGGTLE
1,160.55 2.2 P25940 COL5A3 Collagen alpha-3(V) chain PGQPGIRGPAGH
1,130.63 2.1 P07911 UMOD Uromodulin SVIDQSRVLN






1,047.48 1.8 P07911 UMOD Uromodulin SGSVIDQSRV
1,039.44 1.8
2,327.02 1.7





1,069.60 1.6 P07911 UMOD Uromodulin SRVLNLGPIT
2,636.20 1.5
2,572.21 1.5
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two preferred methods in peptidomics are CE MS [28] and
LC MS [29–31]. Using CE MS method, Wittke et al.
analyzed urine samples collected from renal transplant
patients with AR, STA, and urinary tract infection and
identified a distinct polypeptide pattern [17]. LC-based, LC
MS approach usually involves three main steps: (1)
extraction of peptides, (2) fractionation of extracted peptides
using HPLC, and (3) MS analysis of fractionated peptides
for biomarker discovery purpose. Different strategies could
be applied to fractionate the mixture of peptides. We used
LC MALDI to identify potential biomarkers that could
potentially be used as diagnostic surrogate biomarkers for
acute kidney transplant rejection.
We have made several important findings in this study.
Firstly, we have demonstrated that pooled strategy is a
viable way to screen for potential biomarker peptides in
urine. High throughput “omic” methods require a consid-






Gene Parent protein Peptide sequence
2,236.10 1.5 P27658 COL8A1 Collagen alpha-1
(VIII) chain
QDGIPGQPGFPGGKGEQGLPGLP





1,680.97 78.9 P07911 UMOD Uromodulin VIDQSRVLNLGPITRa
2,604.30 35.2 P61769 B2M B-2 microglobulin LKNGERIEKVEHSDLSFSKDWS
1,615.90 14.8
1,912.06 12.8 P07911 UMOD Uromodulin SGSVIDQSRVLNLGPITRa
956.53 8.9 Q15654 TRIP6 Thyroid receptor-
interacting protein 6
QGRAIPRGT





1,524.90 6.0 P07911 UMOD Uromodulin DQSRVLNLGPITR







1,631.90 4.5 P61769 B2M B-2 microglobulin LLKNGERIEKVEHSDL
982.61 3.6 P07911 UMOD Uromodulin VLNLGPITR
1,755.95 3.4 P07911 UMOD Uromodulin SGSVIDQSRVLNLGPITa
1,768.01 3.3 P07911 UMOD Uromodulin SVIDQSRVLNLGPITRa
1,654.91 2.8 P07911 UMOD Uromodulin SGSVIDQSRVLNLGPI
1,541.80 2.5
1,188.70 2.4 P01042 KNG1 Kininogen-1 KRPPGFSPFR
1,204.60 2.2 Q08174 PCDH1 Protocadherin-1 EEQPPNTLIGS
2,040.16 2.2 P07911 UMOD Uromodulin RSGSVIDQSRVLNLGPITRa




1,578.70 2.0 O75339 CILP Cartilage intermediate
lauer protein
VGRCPVKTCAGQQDN





a Peptides verified in individual samples as illustrated in Fig. 5.
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conflicting opinions about pooled strategy. It is not
advisable to pool samples wherever the aim is to identify
very low abundance peptides because of the risk of losing
the signal [32]. However, pooling strategy helps in quickly
screening for most significant candidates and proceeds
further in the biomarker pathway with verification with
individual samples.
In this effort to discover endogenous peptides that
discriminate AR from stable graft, we had to address several
confounding issues. Patient urine may have a variable
peptide concentration, dependent on the individual’s meal,
drink, and sleep patterns [33], which requires data to be
normalized [34]. In the absence of a consensus “house-
keeping” peptide for normalization, we choose a strategy
that was best available to us. To normalize total peptide
used per analysis, we loaded equal amount (3 nmol) as
quantified by TNBS assay. Another important factor is the
ionization efficiency of the mass spectrometer employed
for MS analysis. We used glu-fibrinopeptide as internal
control for ionization efficiency and performed three MS
scans of 2,000 laser shots per scan moving the laser every
50 shots.
Fig. 4 A sample spectrum of
acute rejection (AR) specific
peptide from MALDI-MS/MS.
A MS/MS spectrum used for
sequencing of one of the of AR
specific peptides from UMOD
(m/z=1,912.06 Da) was made
by MS/MS analysis is shown. In
the inset: portion of MALDI MS
spectrum of showing peptide
peak for the same peptide
(m/z=1,912.06 Da)
Fig. 3 Box plots for four
categories of endogenous uri-
nary peptides signal intensities
when normalized against their
presence in normal healthy con-
trol. Top panel low-abundance
peptides. A Increase in acute
rejection (AR) than stable graft
function (STA). B Decrease in
AR than STA. Bottom panel
high abundance peptides.
C Increase in AR than STA.
D Decrease in AR than STA.
The boxes are bounded by 75th
and 25th percentiles of the data,
and the whiskers extend to the
minimum and maximum values
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The third important outcome of the study is that we
hypothesized that AR-specific signature exists among endog-
enous urinary peptides. The results from our study showed that
such peptides in fact exist (Table 2). The peptides could be
classified in four distinct classes as shown in Fig. 3. Those
four panels provided peptide candidate biomarkers that
collectively distinguish urine from acute rejection patients
from patients with stable graft function. We verified the
trueness of the discovered peptide biomarkers resulted from
the pooled approach using MALDI-TOF, by analyzing five
most significant peptides on individual urine from ten AR
patients and ten patients with stable graft function, including
ten urine samples from nephrotic syndrome urine and ten
urine collected from healthy normal controls. The successful
verification of these peptides supported our pooled approach
in initial screening of biomarkers.
Yet another achievement of this study is that we have
identified 54 peptide fragments among 73 listed in Table 2.
Even though identification endogenous peptides is more
difficult compared to proteolytically cleaved peptides such as
trypsin digested peptides, we identified several endogenous
peptides which belong to either proteins of either renal origin
Fig. 5 An evaluation of the
trueness of the discovery made
by pooled samples with LC
MALDI. A measurement of
potential peptide biomarkers
was made using individual urine
from (1 ten acute rejection;
2 ten stable graft function; 3 ten
healthy control; and 4 ten
nonspecific proteinuria (NS).
Average normalized signal
intensities of the ten samples in
each category have been plotted
with SEM
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or related with kidney dysfunction. Among the proteins
identified include Tamm–Horsfall protein (UMOD), the
most abundant protein in human urine; β-2 microglobulin
(B2M), a cleaved product as well as the intact protein which
has been reported as potential biomarker protein for AR by
two independent groups [13, 35]; kininogen (KNG1),
reported to be related to pathophysiology of hypertension
and renal diseases [36]; and prostaglandin-H2 D-isomerase
is reported to be expressed in kidney tubules (Human Protein
Atlas—http://proteinatlas.org).
Finally, a number of peptide fragments of Tamm–Horsfall
protein were observed to be significantly lower in AR urine
when compared to STA urine and the urine collected from
healthy normal controls. Trueness of this finding has been
verified by analyzing individual samples. This observation of
peptide fragments from other kidney-specific proteins may be
an indication of a possible role of protease and protease
inhibitor activities at the time of acute rejection. In an ongoing
gene-expression analysis of biopsies of AR and STA patients,
we have observed significantly low expression of UMOD
gene (P=0.008) in a total of 64 biopsy microarrays that
included 19 AR and 45 non-AR biopsy samples (Sarwal
et al. 2008, unpublished data). This observation of a consistent
low expression of UMOD at the transcript level as well its
peptides may help us achieve a better insight on possible
events associated with AR and even to investigate THP,
physiological role of which has intrigued many researchers.
The observation of altered concentration of THP peptides
in acute rejection vs stable graft will have to be investigated
further with specific focus on the role of proteases and
protease inhibitor activities. One of the ways to study such
activity is to look for their cleavage pattern to see if they
indicate activation of any specific protease/s. In a published
report, Villanueva et al. identified a signature subset of
serum peptides for three types of solid tumors but also to
link peptide marker profiles for disease conditions directly to
differential protease activity [37]. Such study in case of
urinary peptides is possible with a larger patient cohort and
with appropriate in vitro assays which is out of scope for this
focused report on screening for potential biomarkers.
The important clinical utility aspect of this study is that
the identified potential biomarker peptides will be verified in
subsequent verification step using quantitative approach such
as Multiple Reaction Monitoring (MRM) or enzyme-linked
immunosorbent assays. Such quantitative analysis on a larger
cohort of independent samples will help shorten the list of
biomarkers which then could be taken to clinical trial.
Conclusion
In summary, for the first time, we have shown that LC
MALDI is a useful tool to screen for potential non-invasive
urinary peptide biomarkers for acute rejection. We identified
a set of peptides as potential biomarkers for AR. We tested
the trueness of the discovery on five of the most significant
peptide candidates and demonstrated that LC MALDI on
pooled urine samples for discovery is a reliable strategy for
screening phase of biomarker discovery. A verification study
is now necessary to further the outcome of this study, which
is underway with more patients and disease categories
included.
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